Shi Chuan, Liu Jian-Zhou, Zeng Zheng-Pei, Miao Qi, Fang Li-Gang, Chen Shi, Ping Fan, Sun Hao, Lu Lin, Chen Li-Bo, Fu Yong, Zhao Da-Chun, Yu Chun-Hua, JiaJue Rui-Zhi, Wang Xi, Liu Xing-Rong, Ma Guo-Tao, Zhang Chao-Ji, Pan Hui, Yang Hong-Bo, Wang Yi-Ning, Li Ming, Li Fang, Shen Zhu-Jun, Liang Zhi-Yong, Xing Xiao-Ping, Zhu Wen-Ling
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.
J Endocr Soc. 2023 Jul 10;7(9):bvad093. doi: 10.1210/jendso/bvad093. eCollection 2023 Aug 2.
Paragangliomas located within the pericardium represent a rare yet challenging clinical situation.
The current analysis aimed to describe the clinical characteristics of cardiac paragangliomas, with emphasis on the diagnostic approach, genetic background, and multidisciplinary management.
Twenty-four patients diagnosed with cardiac paraganglioma (PGL) in Peking Union Medical College Hospital, Beijing, China, between 2003 and 2021 were identified. Clinical data was collected from medical record. Genetic screening and succinate dehydrogenase subunit B immunohistochemistry were performed in 22 patients.
The median age at diagnosis was 38 years (range 11-51 years), 8 patients (33%) were females, and 4 (17%) had familial history. Hypertension and/or symptoms related to catecholamine secretion were present in 22 (92%) patients. Excess levels of catecholamines and/or metanephrines were detected in 22 (96%) of the 23 patients who have completed biochemical testing. Cardiac PGLs were localized with I-metaiodobenzylguanidine scintigraphy in 11/22 (50%), and Tc-hydrazinonicotinyl-tyr3-octreotide scintigraphy in 24/24 (100%) patients. Genetic testing identified germline mutations in 13/22 (59%) patients, while immunohistochemistry revealed succinate dehydrogenase (SDH) deficiency in tumors from 17/22 (77%) patients. All patients were managed by a multidisciplinary team through medical preparation, surgery, and follow-up. Twenty-three patients received surgical treatment and perioperative death occurred in 2 cases. Overall, 21 patients were alive at follow-up (median 7.0 years, range 0.6-18 years). Local recurrence or metastasis developed in 3 patients, all of whom had SDH-deficient tumors.
Cardiac PGLs can be diagnosed based on clinical manifestations, biochemical tests, and appropriate imaging studies. Genetic screening, multidisciplinary approach, and long-term follow-up are crucial in the management of this disease.
位于心包内的副神经节瘤是一种罕见但具有挑战性的临床情况。
本分析旨在描述心脏副神经节瘤的临床特征,重点是诊断方法、遗传背景和多学科管理。
确定了2003年至2021年期间在中国北京协和医院诊断为心脏副神经节瘤(PGL)的24例患者。从病历中收集临床数据。对22例患者进行了基因筛查和琥珀酸脱氢酶亚基B免疫组织化学检测。
诊断时的中位年龄为38岁(范围11 - 51岁),8例(33%)为女性,4例(17%)有家族史。22例(92%)患者存在高血压和/或与儿茶酚胺分泌相关的症状。在完成生化检测的23例患者中,22例(96%)检测到儿茶酚胺和/或甲氧基肾上腺素水平升高。11/22例(50%)患者通过131I - 间碘苄胍闪烁显像定位心脏PGL,24/24例(100%)患者通过锝 - 肼基烟酰基 - 酪氨酰3 - 奥曲肽闪烁显像定位。基因检测在13/22例(59%)患者中发现种系突变,而免疫组织化学显示17/22例(77%)患者肿瘤存在琥珀酸脱氢酶(SDH)缺陷。所有患者均由多学科团队进行医疗准备、手术和随访管理。23例患者接受了手术治疗,2例发生围手术期死亡。总体而言,21例患者在随访时存活(中位7.0年,范围0.6 - 18年)。3例患者出现局部复发或转移,所有这些患者的肿瘤均为SDH缺陷型。
心脏PGL可根据临床表现、生化检测和适当的影像学检查进行诊断。基因筛查、多学科方法和长期随访在该疾病的管理中至关重要。